^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    LAG3 overexpression

    i
    Other names: LAG3, Lymphocyte Activating 3, Lymphocyte Activation Gene 3 Protein, Lymphocyte-Activation Gene 3, CD223 Antigen, CD223, LAG-3, FDC
    Entrez ID:
    3902
    Related biomarkers:
    Expression
    Mutation
    Others
    21d
    Monoclonal Antibody against Porcine LAG3 Inhibits Porcine Reproductive and Respiratory Syndrome Virus Infection. (PubMed, Vet Sci)
    Interference of LAG3 expression on PHA-activated lymphocytes promoted PRRSV replication in the co-culture system of monocyte-derived dendritic cells and lymphocytes, whereas overexpression of LAG3 or blocking of the LAG3 signal with mAb 1C2 inhibited PRRSV replication, indicating that PRRSV infection activates the LAG3-signaling pathway, suggesting that this pathway plays an important role in PRRSV pathogenesis. The results obtained lay the foundation for subsequent research on the role of LAG3 in PRRS and other diseases with persistent infection characteristics.
    Preclinical • Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3)
    |
    LAG3 expression • LAG3 overexpression
    8ms
    A novel immune-related lncRNA signature predicts the prognosis and immune landscape in ccRCC. (PubMed, Aging (Albany NY))
    The new risk model may be a new method to predict the prognosis and immune status of ccRCC.
    Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
    |
    LAG3 overexpression
    11ms
    A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact. (ASCO-GI 2024)
    In this study, a prognostic transcriptomic-based signature of 14 genes has been defined and validated for PDAC. This signature clearly identifies two prognostic groups that could constitute the basis for tailored immunotherapy with specific IC inhibitors. LAG-3 is a promising target for immunotherapy in PDAC patients.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule) • TBX21 (T-Box Transcription Factor 21) • BTLA (B And T Lymphocyte Associated) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    |
    PD-1 overexpression • PD-1 expression • LAG3 overexpression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    over1year
    BCR-ABL1-driven exosome-miR130b-3p-mediated gap-junction Cx43 MSC intercellular communications imply therapies of leukemic subclonal evolution. (PubMed, Theranostics)
    BCR-ABL1-driven exosome-miR130a-3p could interact with Cx43, and further impact GJIC in TME. Our findings shed light on how leukemia BCR-ABL1-driven exosome-miR130b-3p could interact with gap-junction Cx43, and further impact GJIC in TME, implications for leukemic therapies of subclonal evolution.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • TNFRSF4 (TNF Receptor Superfamily Member 4) • GJA1 (Gap Junction Protein Alpha 1) • MIR30B (MicroRNA 30b) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • MIR130A (MicroRNA 130a) • MIR30A (MicroRNA 30a)
    |
    LAG3 overexpression • BCR expression • GJA1 overexpression
    over1year
    Clinical Significance and Prognostic Value of the Expression of LAG-3 and FGL1 in Esophageal Squamous Cell Carcinoma. (PubMed, Bull Exp Biol Med)
    Multivariate Cox regression showed that the level of FGL1 and TNM stage were independent prognostic factors of progression-free survival. We speculated that the tumor microenvironment of ESCC induces immunosuppression due to up-regulated expression of LAG-3 and FGL1 in the tumor tissues, which promotes tumor growth.
    Retrospective data • Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • FGL1 (Fibrinogen Like 1)
    |
    LAG3 expression • LAG3 overexpression
    over1year
    Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies (ESMO-GI 2023)
    Integrative molecular analysis of the tumor microenvironment of GAC identifies an Inflamed class of tumors that complements previously proposed tumor-based molecular clusters (CIN, MSI, EBV, GS). Such findings may provide the rationale for exploring novel immunotherapeutic approaches for biomarker-enriched populations in order to improve GAC patient's survival by means of a paradigm shift in precision immune-oncology.
    PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD44 (CD44 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • STING (stimulator of interferon response cGAMP interactor 1) • RHOA (Ras homolog family member A)
    |
    PD-L1 expression • TP53 mutation • PIK3CA mutation • ARID1A mutation • LAG3 expression • LAG3 overexpression • TIGIT overexpression • IFNG expression • CD44 expression
    |
    nCounter® PanCancer IO 360™ Panel
    over1year
    γδ T cells are significantly suppressed in glioma patients but retain their cytotoxic potential (P743) (IMMUNOLOGY 2023)
    Most importantly, this may significantly affect the general fitness of γδ T cells, lowering their potential for immunotherapy. On the other hand, those changes seem to be at least partially reversible as patient-derived γδ T cells retain their cytotoxic potential after in-vitro activation and culture.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD69 (CD69 Molecule) • IL10 (Interleukin 10) • LAMP1 (Lysosomal Associated Membrane Protein 1) • TGFB1 (Transforming Growth Factor Beta 1) • IL17A (Interleukin 17A) • NKG2D (killer cell lectin like receptor K1)
    |
    LAG3 expression • LAG3 overexpression
    almost2years
    Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy. (PubMed, Front Immunol)
    We comprehensively evaluated the expression features of claudin genes and identified a claudin-low phenotype in ccRCC. In addition, its related signature could robustly predict the prognosis and provide guide for personalizing management strategies.
    Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • BAP1 (BRCA1 Associated Protein 1) • LAG3 (Lymphocyte Activating 3) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
    |
    CD8 expression • LAG3 overexpression
    2years
    Coexpression of lymphocyte-activation gene 3 and programmed death ligand-1 in tumor infiltrating immune cells predicts worse outcome in renal cell carcinoma. (PubMed, Int J Immunopathol Pharmacol)
    Both LAG-3⁺ and PD-L1⁺ RCC have adverse pathological features, and their coexpression predicts worse clinical outcomes. Our findings suggest LAG-3 blockade in combination with programmed cell death 1/PD-L1 blockade as a potential therapeutic approach for RCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
    |
    PD-L1 expression • LAG3 expression • LAG3 overexpression
    2years
    A prognostic exosome-related LncRNA risk model correlates with the immune microenvironment in liver cancer. (PubMed, Front Genet)
    Our study showed that exosome-related lncRNAs and the corresponding nomogram could be used as a better index to predict the outcome and immune regulation of liver cancer patients. This signature might provide a new idea for the immunotherapy of liver cancer in the future.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CD276 (CD276 Molecule) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • VSIR (V-Set Immunoregulatory Receptor)
    |
    LAG3 overexpression
    over2years
    DISTINCT IMMUNE-RESPONSE PROFILE OF RICHTER TRANSFORMATION: HIGH EXPRESSION OF IL-10, LAG-3 AND OTHER IMMUNE CHECKPOINT MOLECULES (EHA 2022)
    Overexpression of LAG3 in large neoplastic B-cells of RT, specifically in cases clonally-related to CLL is an important finding that may serve as a diagnostic marker. Checkpoint molecules LAG3 and TIM3 can serve as new immune-therapy targets for the treatment of RT. IL-10 blockade has been shown to enhance T-cell immunity, and may be a potential therapeutic target.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CD79B (CD79b Molecule) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • S100A8 (S100 Calcium Binding Protein A8) • IL10 (Interleukin 10) • S100A9 (S100 Calcium Binding Protein A9) • IL18 (Interleukin 18) • TGFB1 (Transforming Growth Factor Beta 1) • TP63 (Tumor protein 63) • CD40LG (CD40 ligand) • IL1B (Interleukin 1, beta)
    |
    PD-1 overexpression • PD-1 expression • LAG3 expression • LAG3 overexpression • IL10 overexpression
    |
    Oncomine™ Immune Response Research Assay
    over2years
    NLRP3 promotes immune escape by regulating immune checkpoints: A pan-cancer analysis. (PubMed, Int Immunopharmacol)
    In conclusion, our research demonstrated the role of NLRP3 in pan-cancer, especially in LIHC. Inhibition of NLRP3 promoted the killing effect of T cells to cancer cells by repressing the expression of immune checkpoints.
    Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    PD-L1 expression • TMB-L • LAG3 expression • LAG3 overexpression
    almost3years
    LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway. (PubMed, Cell Mol Biol Lett)
    LAGE3 enhanced the malignant phenotypes of HCC by promoting the JNK and ERK signaling pathway.
    Journal
    |
    LAG3 (Lymphocyte Activating 3) • MAPK8 (Mitogen-activated protein kinase 8)
    |
    LAG3 expression • LAG3 overexpression
    |
    SCH772984 • SP600125
    almost3years
    CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy. (PubMed, Cancers (Basel))
    This pilot study proposes hypotheses for understanding the resistance to immunotherapies in patients with Hodgkin lymphoma. Hodgkin lymphoma exposed to anti-PD-1 correlated in tumor microenvironment with an immune depletion of CD8+ T lymphocytes and overexpression of LAG-3 on CD4+ helper T lymphocytes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator) • CD68 (CD68 Molecule) • BTLA (B And T Lymphocyte Associated)
    |
    LAG3 expression • LAG3 overexpression
    3years
    Overexpression of LAG3, TIM3 and A2aR in adenoid cystic carcinoma and mucoepidermoid carcinoma. (PubMed, Oral Dis)
    These results suggested that LAG3, TIM3 and A2aR are overexpressed in AdCC and MEC, may promote migration of SACC-LM cell and correlated with TGF-β1 and oncogenic signaling pathways.
    Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    LAG3 expression • HAVCR2 expression • LAG3 overexpression
    over3years
    Analysis of LAGEs Family Gene Signature and Prognostic Relevance in Breast Cancer. (PubMed, Diagnostics (Basel))
    Significant associations of LAGE family genes were correlated with the cell cycle, focal adhesion, and extracellular matrix (ECM) receptor interactions as indicated by functional enrichment analyses. Collectively, LAGE family members' gene expression levels were related to adverse clinicopathological factors and prognoses of BRCA patients; therefore, LAGEs have the potential to serve as prognosticators of BRCA patients.
    Journal • Gene Signature • BRCA Biomarker
    |
    LAG3 (Lymphocyte Activating 3) • BRCA (Breast cancer early onset) • CTAG1B (Cancer/testis antigen 1B) • CTAG1A (Cancer/Testis Antigen 1A) • CTAG2 (Cancer/testis antigen 2)
    |
    LAG3 expression • LAG3 overexpression